Mirum Pharmaceuticals (MIRM) Change in Accured Expenses (2019 - 2026)

Mirum Pharmaceuticals' Change in Accured Expenses history runs 8 years deep, the most recent figure standing at $57.2 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 387.72% year-over-year to $57.2 million in Q1 2026; TTM through Mar 2026 was $95.6 million, a 134.5% increase from a year earlier, with the FY2025 full-year figure at $50.1 million, up 24.29% from the prior year.
• Change in Accured Expenses grew to $57.2 million in Q1 2026 per MIRM's latest filing, from $3.4 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $57.2 million in Q1 2026 and bottomed at -$8.1 million in Q1 2022.
• The 5-year median for Change in Accured Expenses is $9.3 million (2024), against an average of $10.9 million.
• Across the five-year window, Change in Accured Expenses sank 146.84% in 2022 and jumped 250660.0% in 2023, its largest moves.
• Year by year, Change in Accured Expenses stood at -$5000.0 in 2022, then soared by 250660.0% to $12.5 million in 2023, then retreated by 25.45% to $9.3 million in 2024, then tumbled by 63.13% to $3.4 million in 2025, then soared by 1562.62% to $57.2 million in 2026.
• Per Business Quant, the three latest MIRM Change in Accured Expenses figures stand at $57.2 million (Q1 2026), $3.4 million (Q4 2025), and $24.3 million (Q3 2025).